Skin cancer · Lancet Reg Health Eur · 2024
The paper’s summary: 29.8% had severe drug side effects. That’s really the any-cause rate. Drug-linked: 18.5%.
Share of the 151 patients with at least one severe health problem
The paper says
A study gave 151 people with advanced skin cancer the drug cemiplimab. A main goal was counting severe side effects: problems doctors judged the drug may have caused. The paper’s summary, the short overview most readers see, reports 68 of them, affecting 29.8% of patients.
Its own data show
The paper’s results give both numbers, but for severe health problems from any cause: 68 problems in 45 of 151 patients (29.8%; some had several). Only 42 of those problems were linked to the drug, in 28 of 151 patients (18.5%). The paper’s table of drug-linked problems also adds up to 42.
A health problem during treatment isn’t always the drug’s doing; doctors judge which ones the drug may have caused. Studies like this show how older, frailer patients cope with a drug. Anyone taking the rate from the summary gets 1.6 times the drug-linked one: the drug looks worse than the paper’s own data show.